Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Shelf-life for Accrufer® extended to 48 months in the US

London, UK, 27 October 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that US Food and Drug Administration ('FDA') has approved the extension of the expiration for Accrufer® (ferric maltol) from 36 months to 48 months.

Greg Madison, CEO of Shield Therapeutics, stated: "Over the past year, we have doubled the shelf-life or time to expiry for Accrufer® from 24 to 48 months.  Not only does this confirm the stable and robust nature of the capsule formulation of Accrufer®, but also provides additional supply chain flexibility and simplifies global logistics as we continue to support our growing US business and our license partners across the globe."

For further information please contact:

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group